Stockwatch: Almost all roads lead to M&A
This article was originally published in Scrip
Executive Summary
Second-quarter earnings season turned on a sixpence last week. After the worries of falling sales, earnings and currencies from the previous two weeks, suddenly the world was a better place with all roads leading to mergers and acquisitions (M&A). Indeed, if you believed all the research published by investment bank analysts last week, all the life science sector's ills can be cured by M&A – although rationally that can't be true since we would eventually end up with only one life science company.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.